<DOC>
	<DOCNO>NCT02042053</DOCNO>
	<brief_summary>This study intents provide initial evaluation utility positron emission tomography magnetic resonance ( PET/MR ) image measure prediction immunological response Sipuleucel T ( SipT ) therapy .</brief_summary>
	<brief_title>PET/MR Assessment Sipuleucel T Treatment Metastatic Castration Resistant Prostate Cancer</brief_title>
	<detailed_description>Recent study treatment prostate cancer stimulation adaptive immune response indicate linear measurement compute tomography ( CT ) nuclear scan use assess tumor response Response Evaluation Criteria Solid Tumors ( RECIST ) inadequate value progression-free survival ( PFS ) predictive surrogate endpoint survival lose . The objective study provide initial evaluation utility PET/MR imaging measure prediction immunological response SipT therapy . Investigators expect identify '' imaging-signature '' response SipT base change metabolism , perfusion , oxygenation cellularity metastasis correlation immunological clinical response . This approach help elucidate mechanism activity dynamic immune antitumor response SipT vivo identify new parameter tumor response predictive value current RECIST PFS standard .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men ≥ 18 year age History prostate cancer treat androgen deprivation Serum Testosterone level &lt; 50 ng/mL Established asymptomatic minimally symptomatic metastasis Eastern Cooperative Oncology Group ( ECOG ) performance status≤2 Accept term image modality performance preestablished time point describe protocol consent Accept term immunemonitoring blood draw performance preestablished time point describe protocol consent Patients steroid ( prednisone 10mg daily hydrocortisone 20 mg daily ) alone combination Zytega ketoconazole prior enrollment eligible Patients steroid underlie chronic condition eligible . ( prednisone 10 mg daily , dexamethasone &lt; 2 mg daily fludrocortisone 0.1 mg daily orally ) Chemotherapy radiation therapy treatment within 21 day SipuleucelT ECOG performance status &gt; 2 Prior treatment SipuleucelT Patients history another primary malignancy within last 2 year curatively treat , exclude basal squamous cell carcinoma skin Patients know positivity human immunodeficiency virus ( HIV ) hepatitis C ; baseline test HIV hepatitis C require Patients significant history noncompliance medical regimen inability grant reliable informed consent Active spinal cord compression .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>image</keyword>
	<keyword>diagnostic</keyword>
	<keyword>castration resistant</keyword>
	<keyword>metastatic prostate cancer</keyword>
	<keyword>immunotherapy</keyword>
</DOC>